Showing results (461-470 of 535) with videos related to
Sort By:
Pageof 54
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.Blood Advances|January 11, 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Nitin Jain, et al.Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemiaDaniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.Pageof 54